explore -WSS

explore

author：entertainment 2025-08-19 20:47:50 - browse：514

NEW ORLEANS — For some patients suffering with certain blood cancers, CAR-T therapy can offer the tantalizing chance to end their disease with a single treatment.

But the immunotherapy takes time to manufacture, and patients often have to wait weeks to actually receive an infusion once they’re eligible. For some patients with especially aggressive cancer, they can die while waiting for the therapy to arrive.

That’s spurred CAR-T manufacturers to find ways to speed up manufacturing. The industry is testing newer — and possibly better — CAR-T cells that can be made more quickly. Researchers working with Novartis presented Phase 1 clinical trial data Sunday on a new CAR-T cell made with a rapid manufacturing process at the annual American Society of Hematology meeting.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Alkermes shareholders re
Next article： Can Threads overtake X, formerly known as Twitter? Experts weigh in.

knowledge

focus

WSS

Vertex non

Infectious disease expert Jeanne Marrazzo assumes Fauci role

NYC struggling to keep up with demand of supporting asylum seekers, Mayor Adams says

FTX founder Sam Bankman

Mega Millions pot grows to $1.25 billion after no winner

NIH launches clinical trials and new research office for long Covid

entertainment

explore

explore

United colonoscopy coverage change 'may cost lives,' doctors say

Judge rejects Trump's counterclaim against E. Jean Carroll

Wildfire smoke exposes gaps in outdoor worker protections

Judge rejects Trump's counterclaim against E. Jean Carroll

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Micronoma's microbiome cancer diagnostic approach under fire

Wildfire smoke exposes gaps in outdoor worker protections

Trump attorney outlines possible Jan. 6 legal defenses, but some experts are skeptical

Cancer drug shortages should be causing more outrage

Listen: Biogen's situation, Wegovy's risks, & biotech insider trading

focus

No plane should take off without an EpiPen onboard

Can Threads overtake X, formerly known as Twitter? Experts weigh in.

NIH launches clinical trials and new research office for long Covid

‘Oppenheimer’ and the risks of AI in health care

The high personal cost of affirmative action for Black doctors

Cheesesteak restaurant owner explains his secret sauce, the viral Malibu Barbie Dream Drizzle

leisure time

knowledge

focus

knowledge